RecombinantLeishmania majorSecreting Biologically Active Granulocyte-Macrophage Colony-Stimulating Factor Survives Poorly in Macrophages In Vitro and Delays Disease Development in Mice
- 1 November 2003
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 71 (11) , 6499-509
- https://doi.org/10.1128/iai.71.11.6499-6509.2003
Abstract
Leishmaniais an intracellular pathogen that replicates inside macrophages. Activated macrophages produce a specific subset of cytokines that play an important role in the control ofLeishmaniainfections. As part of our interest in developing suicide parasites that produce abortive infections for the purposes of vaccination, we engineered recombinantLeishmania majorstrains producing biologically active granulocyte-macrophage colony-stimulating factor (GM-CSF). We showed that GM-CSF is being produced in the phagosomes of infected macrophages and that it can be detected in the culture supernatants of both infected macrophages and extracellular parasites. Our data support the notion that GM-CSF secreted by both developmental forms of recombinantL. majorcan activate macrophages to produce high levels of proinflammatory cytokines such as interleukin-1β (IL-1β), IL-6, and IL-18 and various chemokines including RANTES/CCL5, MIP-1α/CCL3, MIP-1β/CCL4, MIP-2/CXCL2, and MCP-1/CCL2, which enhance parasite killing. Indeed, GM-CSF-expressing parasites survive poorly in macrophages in vitro and produce delayed lesion development in susceptible BALB/c mice in vivo. Selective killing of intracellularLeishmaniaexpressing cytokine genes capable of activating cellular responses may constitute a promising strategy to control and/or prevent parasitic infections.Keywords
This publication has 65 references indexed in Scilit:
- Monocyte chemotactic protein-1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN-γ and is antagonized by IL-4European Journal of Immunology, 2000
- Potentiality of Interleukin-18 as a Useful Reagent for Treatment and Prevention ofLeishmania majorInfectionInfection and Immunity, 2000
- Enhanced Th2-like responses in IL-1 type 1 receptor-deficient miceEuropean Journal of Immunology, 1998
- INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in BiologyAnnual Review of Immunology, 1998
- IGIF Does Not Drive Th1 Development but Synergizes with IL-12 for Interferon-γ Production and Activates IRAK and NFκBImmunity, 1997
- Enhancement of Leishmanicidal Activity of Human Macrophages Against Leishmania major and Leishmania donovani Infection Using Recombinant Human GranuloZentralblatt für Bakteriologie, 1996
- The Regulation of Immunity to Leishmania MajorAnnual Review of Immunology, 1995
- Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral leishmaniasisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1994
- Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma.The Journal of Experimental Medicine, 1987
- Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages.The Journal of Experimental Medicine, 1987